On label and off label drug use in the treatment of endometriosis

The use of “off-label” medications in the treatment of endometriosis is widespread. After an overview of Food and Drug Administration–approved treatments, this article reviews the use of “off-label” medications for endometriosis.

Like Comment


Alexander M. Quaas, M.D., Ph.D., Elizabeth A. Weedin, D.O., Karl R. Hansen, M.D., Ph.D.

Volume 103, Issue 3, Pages 612-625


Endometriosis, characterized by the presence of endometrial glands and stroma in extrauterine locations, is a significant cause of pelvic pain and infertility, as well as a major health care burden. Although Food and Drug Administration (FDA)–approved treatments are available, the use of “off-label” medications for endometriosis is widespread. In this review, we provide an overview of the current FDA-approved treatments, followed by a detailed review of the major “off-label” treatments being used in the United States and worldwide, including efficacy, side effects, drug interactions, contraindications, and anomaly risks.

Read the full text at: http://www.fertstert.org/article/S0015-0282(15)00041-2/fulltext

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.